Nordic Nanovector ASA has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer─1 phase 1b trial with Betalutin
Original Article: Nordic updates on CTA for Archer─1 and PARADIGME trials in Norway